PDT Partners’s Harvard Bioscience HBIO Stock Holding History

PDT Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,040	Closed	-$45K	–	433
2019 Q1	$45K	Sell	1,040 -320	-24%	-$11.6K	﹤0.01%	428
2018 Q4	$43K	Sell	1,360 -1,000	-42%	-$39.4K	﹤0.01%	454
2018 Q3	$124K	Sell	2,360 -390	-14%	-$21.9K	0.01%	454
2018 Q2	$147K	Sell	2,750 -300	-10%	-$15.4K	0.01%	489
2018 Q1	$153K	Buy	+3,050	New	+$137K	0.01%	534

Other funds holding HBIO

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PDT Partners's HBIO Position: Q2 2019 in Review

PDT Partners sold out of Harvard Bioscience (HBIO) in Q2 2019, closing a stake of 1,040 shares — an estimated $45K sold.

PDT Partners first reported a position in HBIO in Q1 2018 and held it in 5 quarters. The position peaked at $153K in Q1 2018. 78 funds tracked by Wall St. Rank hold HBIO as of Q2 2019.

PDT Partners reported no remaining Harvard Bioscience position as of Q2 2019 after selling out during the quarter.
PDT Partners sold 1,040 Harvard Bioscience shares in Q2 2019, an estimated $45K.
PDT Partners first reported a position in Harvard Bioscience in Q1 2018 and held it in 5 quarters.
PDT Partners's Harvard Bioscience position peaked at $153K in Q1 2018.
78 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2019.

Based on PDT Partners's 13F filing for Q2 2019, filed 14 Aug 2019.